Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polaprezinc
- Development stage
- Phase 4
- Lead developer
- Hamari Chemicals
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Administration
- Oral
01
Overview
Polaprezinc is an orally bioavailable chelate composed of zinc and L-carnosine, primarily used as a gastric mucosal protective agent. It is approved in Japan for the treatment and prevention of gastric ulcers and gastritis. Polaprezinc exerts cytoprotective, antioxidant, anti-ulcer, and anti-inflammatory effects by increasing the expression of antioxidant enzymes (such as SOD-1/2, HO-1), inhibiting pro-inflammatory cytokines (including TNF-alpha and IL-6), upregulating growth factors (PDGF-B, VEGF, NGF), and stimulating heat shock proteins (HSP90/70/60/47/27/10). Its mechanism includes scavenging reactive oxygen species in the gastric mucosa to protect cells from oxidative damage while promoting tissue repair. Polaprezinc also inhibits nuclear factor-kappaB activity to reduce inflammation and has demonstrated efficacy in improving healing rates for peptic ulcers as well as potential benefits for oral mucositis associated with cancer therapy[1][2][3][4][5][6].
- Brand names
- PromacPepZin GI
- Other names
- zinc L-carnosinezinc-carnosine complexZnC
02
Targets
NGF (Nerve growth factor)HSP90AA1 (Heat shock protein HSP90-alpha)HSP90AB1 (Heat shock protein HSP 90-beta)IL3 (IL-3)IL-6 (Interleukin 6)PDGFRB (Platelet-derived growth factor receptor beta)TNFA (Tumor necrosis factor alpha (soluble))VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on polaprezinc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polaprezinc.